Top

Published in:

Open Access 01-12-2020 | Edema | Research article

Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes

Authors: Javier Zarranz-Ventura, Barbara Romero-Núñez, Carolina Bernal-Morales, Daniel Velazquez-Villoria, Anna Sala-Puigdollers, Marc Figueras-Roca, Sergio Copete, Laura Distefano, Anna Boixadera, Jose García-Arumi, Alfredo Adan, on behalf of the Hospital Clínic - Hospital Vall de Hebron Intravitreal Dexamethasone Implant study group

Published in: BMC Ophthalmology | Issue 1/2020

Abstract

Background

To identify different response patterns to intravitreal dexamethasone implants (IDI) in naïve and previously treated (PT) diabetic macular edema (DME) eyes in a real-life setting.

Methods

342 IDI injections (203 DME eyes) were included. Number of IDI injections, percentage (%) of eyes with 1, 2, 3 and ≥ 4 injections, time to reinjections, visual acuity (VA), intraocular pressure (IOP) and central retinal thickness (CRT) were evaluated for naïve and PT DME eyes over 24 months.

Results

Mean number of injections was significantly lower in naïve vs PT DME eyes (1.40 ± 0.9 vs 1.82 ± 0.9, p < 0.001). The percentage of eyes receiving 1 injection was significantly higher in naïve vs PT DME eyes (76.1 vs 47.7), (p < 0.001). However, it was significantly lower for 2 (16.4 vs 29.4), or 3 injections (1.4 vs 17.6) (both p < 0.001), with no differences in eyes receiving ≥4 injections (5.9 vs 5.1 respectively, p = 0.80). Mean time to reinjection was not significantly different between both groups for the second, third and fourth injection (9.6 ± 4.0 vs 10.0 ± 5.5, p = 0.75, 13.2 ± 4.0 vs 16.0 ± 3.5, p = 0.21 and 21.7 ± 3.8 vs 19.7 ± 5.8, p = 0.55). VA scores were consistently better in naïve vs PT DME eyes at all studied timepoints, with no significant differences in CRT reduction or adverse effect rates.

Conclusion

Naïve DME eyes received lower number of IDI injections and showed better VA levels than PT DME eyes for 24 months in a real-world setting. This data supports the IDI use in early DME stages and provide further evidence of better IDI response when used as first-line therapy.

Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1–32. https://doi.org/10.1016/j.survophthal.2008.10.001.PubMedCrossRef

Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88(3):279–91.PubMedCrossRef

Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis. 2007;10:103–17. https://doi.org/10.1007/s10456-007-9067-z.PubMedCrossRef

Gillies M, Sutter F, Simpson J, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular EdemaTwo-year results of a double-masked, placebo-controlled. Randomized Clin Trial Ophthalmol. 2006;113:1533–8. https://doi.org/10.1016/j.ophtha.2006.02.065.CrossRef

Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2.PubMedCrossRef

Zarranz-Ventura J, Mali JO. Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg dexamethasone Intravitreal implants in diabetic macular edema using the area-under-the-curve method: the CONSTANT analysis; 2020. https://doi.org/10.2147/OPTH.S253370.CrossRef

Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology. 2010;117:1134–1146.e3. https://doi.org/10.1016/j.ophtha.2010.03.032.PubMedCrossRef

Lowder C. Dexamethasone Intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545. https://doi.org/10.1001/archophthalmol.2010.339.PubMedCrossRef

Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone Intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–14. https://doi.org/10.1016/j.ophtha.2014.04.024.PubMedCrossRef

10.

Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–81.PubMedCrossRef

11.

Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, et al. Bevacizumab or dexamethasone implants for DME: 2-year results (the BEVORDEX study). Ophthalmology. 2016;123:1399–401. https://doi.org/10.1016/j.ophtha.2015.12.012.PubMedCrossRef

12.

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222. https://doi.org/10.1159/000458539.PubMedCrossRef

13.

Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M. Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema. Ophthalmologica. 2015;233(3-4):176–85.PubMedCrossRef

14.

Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the international retina group real-life 24-month multicenter study. IRGREL-DEX Study. Retina. 2019;39(1):44–51.PubMedCrossRef

15.

Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories ‘hand motion’ and ‘counting fingers’ using the Freiburg visual acuity test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–42.PubMedCrossRef

16.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef

17.

Maturi RK, Pollack A, Uy HS, Varano M, Gomes AMV, Li XY, et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study. Retina. 2016;36(6):1143–52.PubMedCrossRef

18.

Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–23.PubMedCrossRef

19.

Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li XY, Cui H, et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol. 2015;15:150.PubMedPubMedCentralCrossRef

20.

Malcles A, Dot C, Voirin N, Agard E, Vie AL, Bellocq D, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina. 2017;37:753–60.PubMedCrossRef

21.

Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141–6.PubMedCrossRef

22.

Totan Y, Güler E, Güraʇaç FB. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res. 2016;41(1):107–13.PubMedCrossRef

23.

Bansal P, Gupta V, Gupta A, Dogra MR, Ram J. Efficacy of Ozurdex implant in recalcitrant diabetic macular edema—a single-center experience. Int Ophthalmol. 2016;36(2):207–16.PubMedCrossRef

24.

Bonnin S, Dupas B, El Sanharawi M, Perol J, Erginay A, Tadayoni R, et al. Efficacy of dexamethasone intravitreal implant for the treatment of diabetic macular edema. Eur J Ophthalmol. 2015;25(5):448–53.PubMedCrossRef

25.

Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DAL, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: The CHROME study. Clin Ophthalmol. 2015;9:1255–68.PubMedPubMedCentral

26.

Guigou S, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, et al. Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica. 2015;233(3-4):169–75.PubMedCrossRef

27.

Chhablani J, Bansal P, Veritti D, Sambhana S, Sarao V, Pichi F, et al. Dexamethasone implant in diabetic macular edema in real-life situations. Eye. 2016;30(3):426–30.PubMedCrossRef

28.

Zhioua I, Semoun O, Lalloum F, Souied EH. Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema. Retina. 2015;(7):35, 1429–1435.

29.

Chatziralli I, Theodossiadis P, Parikakis E, Dimitriou E, Xirou T, Theodossiadis G, et al. Dexamethasone Intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther. 2017;8(6):1393–404.PubMedPubMedCentralCrossRef

30.

Matonti F, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, et al. Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol. 2016;26(5):454–9.PubMedCrossRef

31.

Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, et al. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica. 2012.

32.

Moon BG, Lee JY, Yu HG, Song JH, Park YH, Kim HW, et al. Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. J Ophthalmol. 2016;2016:9810270.PubMedPubMedCentral

33.

Nunes S, Pereira I, Santos A, Bernardes R, Cunha-Vaz J. Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME. Br J Ophthalmol. 2010;94(9):1201–4.PubMedCrossRef

34.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.PubMedCrossRef

35.

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22.PubMedCrossRef

36.

Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–65.PubMedCrossRef

37.

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25.PubMedCrossRef

38.

Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A, et al. OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology. 2018;125(2):267–75.PubMedCrossRef

39.

Zur D, Iglicki M, Sala-Puigdollers A, Chhablani J, Lupidi M, Fraser-Bell S, et al. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 2019:1–7.

40.

Fonollosa A, Zarranz-Ventura J, Valverde A, Becerra E, Bernal-Morales C, Pastor-Idoate S, et al. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study. Graefes Arch Clin Exp Ophthalmol. 2019;257:2381–90.PubMedCrossRef

41.

Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J, Alba-Linero C, Alforja S, Esquinas C, et al. Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema. Investig Ophthalmol Vis Sci. 2019;60:1336–43.CrossRef

42.

Busch C, Zur D, Fraser-Bell S, Laíns I, Santos AR, Lupidi M, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55:789–96. https://doi.org/10.1007/s00592-018-1151-x.PubMedCrossRef

43.

Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev. 2018;2018.

44.

Comet A, Gascon P, Sauvan L, Donnadieu B, Matonti F. INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 6 months follow-up study. Acta Ophthalmol. 2019;97:e937–8.PubMedCrossRef

45.

Zarranz-Ventura J, Sala-Puigdollers A, Velazquez-Villoria D, Figueras-Roca M, Copete S, Distefano L, et al. Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. PLoS One. 2019;14(1):e0209997.PubMedPubMedCentralCrossRef

46.

Rajesh B, Zarranz-Ventura J, Fung AT, Busch C, Sahoo NK, Rodriguez-Valdes PJ, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39–46.PubMedCrossRef

Title: Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
Authors: Javier Zarranz-Ventura
Barbara Romero-Núñez
Carolina Bernal-Morales
Daniel Velazquez-Villoria
Anna Sala-Puigdollers
Marc Figueras-Roca
Sergio Copete
Laura Distefano
Anna Boixadera
Jose García-Arumi
Alfredo Adan
on behalf of the Hospital Clínic - Hospital Vall de Hebron Intravitreal Dexamethasone Implant study group
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Edema
Dexamethasone
Published in: BMC Ophthalmology / Issue 1/2020
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/s12886-020-01716-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Retinal vascular abnormalities and their associations with cardiovascular and cerebrovascular diseases: a Study in rural southwestern Harbin, China

Glistening formation in a new hydrophobic acrylic intraocular lens

Comparison of outcomes after topography-modified refraction versus wavefront-optimized versus manifest topography-guided LASIK

Swept-source optical coherence tomography angiography of diabetic papillopathy: a case report

Clinical characteristics and prognosis of Total Rhegmatogenous retinal detachment: a matched case-control study

Leber’s hereditary optic neuropathy following unilateral painful optic neuritis: a case report